Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment
Authors:
- 5 October 2016
- journal article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 12 (5) , 3353-3358
Abstract
The rate of sustained virologic response (SVR) has increased in patients with chronic hepatitis C (CHC; genotype 1) since triple treatment with pegylated interferon (PEG-IFN), ribavirin (RBV) and telaprevir (TVR) was included in Japanese health insurance. However, side effects such as high-grade anemia and skin disorders means it is important to investigate the extent to which quality of life (QOL) is maintained during treatment. The impact on health-related (HR) QOL, as a result of TVR-based triple treatment was investigated long-term (48 weeks) in 34 patients (18 men, 16 women) following TVR-based triple treatment, using the 36-item short form health survey (SF-36). While scores for physical health were significantly lower during treatment, an improvement was seen in patients who showed complete response to treatment from 12 weeks following treatment (P<0.05). HRQOL improved significantly following completion of TVR-based triple treatment in these complete-responders, with higher scores compared with those prior to treatment. Anemia and skin symptoms appeared frequently during treatment and scores for physical health dropped. Particular care needs to be taken in regards to the management of side effects during TVR treatment. Further evaluations using the SF-36 may help in controlling doses to achieve SVR.Keywords
This publication has 20 references indexed in Scilit:
- Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational studyLiver International, 2011
- Telaprevir for Previously Treated Chronic HCV InfectionNew England Journal of Medicine, 2010
- The Lived Experience of Treatment for Hepatitis CGastroenterology Nursing, 2009
- Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV InfectionNew England Journal of Medicine, 2009
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- The impact of diagnosis of hepatitis C virus on quality of lifeHepatology, 1999
- Translation, Adaptation, and Validation of the SF-36 Health Survey for Use in JapanJournal of Clinical Epidemiology, 1998
- Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) ProjectJournal of Clinical Epidemiology, 1998
- Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosisHepatology, 1998
- International quality of life assessment (IQOLA) projectQuality of Life Research, 1992